Authors
Latest:
COVID-19 Booster Shots and the FutureKey opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Latest:
COVID-19 Convalescent Plasma: What Is Its Role in Therapy?The key is using the right dose on the right patient at the right time.
Latest:
And Then There Was One: HCV Elimination in the Coinfected PopulationThe evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.
Latest:
Enhancing Outcomes in Outpatient Parenteral Antimicrobial TherapyNabin K. Shrestha, MD, MPH, evaluates the Cleveland Clinic's Outpatient Parenteral Antimicrobial Therapy (OPAT) program, revealing its effectiveness in managing infections while highlighting challenges in monitoring and the impact of infectious disease pharmacists on patient outcomes.
Latest:
Restoring Hope by Restoring Gut Flora: Rebyota and the Future of Combating Recurrent CDIAlthough fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.
Latest:
The Roles of Misinformation, Disinformation, and Confirmation Bias in Public Health DiscourseKatrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.
Latest:
COVID-19 Booster Shots and the FutureKey opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Latest:
Final Diagnosis: Pott Puffy Tumor With Subdural EmpyemaA rare case of Pott puffy tumor occurs in an atypical patient with no risk factors, likely due to untreated sinus infection.
Latest:
Our Price for Not Aiming Higher: Long COVID Is Here to StayGuest author Seth Lederman, MD, calls Long COVID "one of the most pressing global health threats I have seen since fighting HIV/AIDS."
Latest:
The Future of Influenza Vaccination: Insights from FluGen’s M2SR Vaccine StudyPaul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.
Latest:
Infection Control: AP Technology's Impact on Reducing HAIs and AMR PathogensDeborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.
Latest:
COVID-19 Infection Does Not Impact Symptom Severity or Disability Trajectory in Multiple SclerosisBetween those infected and uninfected with COVID-19, investigators observed no differences in symptom trajectories, assessed through SymptoMScreen.
Latest:
A Novel Approach to Infectious Disease SurveillanceThe International Society for Infectious Diseases (ISID) ProMED surveillance system is a way for clinicians and interested ID stakeholders to be aware of local outbreaks and follow-up in response to get more information on them.
Latest:
Lifting the Medical and Economic Burden of AMR in the USThis bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.
Latest:
Dose Optimization as a Strategy to Improve Clinical Outcomes and Suppress Antimicrobial ResistanceFrom the discovery of penicillin to PK-PD principles: A brief historical overview and what we have learned from recent clinical trials.
Latest:
Disseminated Gonococcal Infection Complicated by Suspected Osteomyelitis of Humeral HeadGonococcal septic polyarthritis is an uncommon manifestation of N gonorrhoeae infection, but has increased by about 40% in recent years.
Latest:
Community-Acquired Candida Glabrata Empyema: An Atypical Diagnosis Not to MissAlthough this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Latest:
Amoxicillin Treatment for Syphilis: Can an Old Drug Learn a New Trick?With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.
Latest:
Daptomycin as Frontline Therapy for MRSA Bacteremia: Has the Time Come?Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.
Latest:
Practice Pearls for Treatment of Respiratory InfectionsTina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Latest:
Amped-up Enterobacterales DebateDemystifying clinical data for treating invasive AmpC-harboring Enterobacterales.
Latest:
Impact of Inpatient Pharmacist Review of Discharge AntibioticsA food for thought as an ambulatory antibiotic stewardship initiative.
Latest:
Ready, Set, Cabenuva: Implementing Cabotegravir/RilpivirineThis novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Latest:
Mpox and Concerns Around the Disease in the United StatesScott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.
Latest:
The Next Generation of COVID-19 Vaccines and BoostersWill there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Latest:
RSV Prophylaxis: Palivizumab, Nirsevimab, and MoreCurrent prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.
Latest:
Hepatitis B Vaccination Increases Survival of Patients with Chronic Liver DiseaseHepatitis B virus vaccination shown to to significantly improve survival rates for patients with chronic hepatitis C, nonalcoholic liver disease, and liver cirrhosis.
Latest:
No Significant Difference Between Doxycycline and Minocycline for Bone and Joint InfectionsAt MAD-ID 2025, William R Mikesell, PharmD, presented data showing 20% vs 16% treatment failure rates in doxycycline and minocycline groups.
Latest:
Advancing C diff Management: Fidaxomicin, Microbiome Therapies, and StewardshipAt MAD-ID 2025, Rachel M. Kenney, PharmD, discusses treatment shifts, microbiome innovations, and pharmacists' roles in optimizing outcomes.
